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Avaliação dos valores séricos de troponina I cardíaca em crianças menores de 1 ano de idade
Evaluation of serum cardiac troponin I values in
children less than 1 year of age
Abstract
Objective: The objective is to verify the cardiac troponin
I values in children less than 1 year of age without clinical
cardiac dysfunction.
Methods: The cardiac troponin I values were determined
in 99 children less than 1 year of age, including term infants
without diseases related to cardiac dysfunction using the
specific kit Opus T Troponin I (cTn) (Dade Behring Inc. -
Newalk, DE 19714, USA).
Results: All children have values of cardiac troponin I
less than 0.1 ng/ml.
Conclusion: We verified that the cardiac troponin I
value is less than 0.1 ng/ml in children less than 1 year,
including term infants without cardiac dysfunction,
when analized by the kit Opus T Troponin I (cTn) test
modules.
Descriptors: Child. Troponin I/blood. Reference values.
Resumo
Objetivo: Verificar os valores séricos para troponina I
cardíaca em crianças abaixo de um ano de idade, sem disfunção
cardíaca clínica.
Métodos: Os níveis séricos de troponina I cardíaca foram
determinados em 99 crianças com idade abaixo de um ano,
incluindo-se recém-nascidos a termo, sem doenças
relacionadas a comprometimento da função cardíaca
identificável clinicamente, por meio do kit específico Opus T
Troponin I (cTn) (Dade Behring Inc. - Newalk, DE 19714, USA).
Resultados: A dosagem sérica de troponina I cardíaca
apresentou, em todos os pacientes, valor menor que 0,1 ng/ml.
Conclusão: Verificamos que o valor da dosagem sérica de
troponina I cardíaca é menor do que 0,1 ng/ml para pacientes
pediátricos, sem disfunção cardíaca, desde recém-nascidos a
termo até um ano de idade, quando realizada por meio do kit
Opus T Troponin I (cTn) test modules.
Descritores: Criança. Troponina I/sangue. Valores de
referência.
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INTRODUCTION
Discovered by Setsuro Ebashi [1], in 1963, the troponins
constitute a complex of proteins which modulates the
velocity and the strength of striated muscle contraction.
The complex consists of three subunits: Troponin T (TnT),
responsible for binding the complex to tropomyosin;
Troponin C (TnC) is a calcium-binding protein and has a
key role in muscle contraction; and Troponin I (TnI) inhibits
muscle contraction [2].
TnI can be found in three isoforms with different protein
structures determined by distinct and specific genes for
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each isoform [3]. Two isoforms are present in the skeletal
muscle, one in fast-twich fibers and other in slow-twich
fibers. The third isoform, present in the myocardium, é called
Cardiac Troponin I (cTnI) [4].
The structural difference between TnI isoforms allowed
that Cummins et al. [5] to develop the first radioimmunoassay
capable of identify the release of cTnI in the acute myocardial
infarction (AMI) and to publish their results in 1987.
The improvement of the method [6] and the great number
of studies investigating its usefulness in the diagnosis of
myocardial injury [7] have made it to become one of the
major biochemical markers of AMI [8].
In pediatrics, researches are focused on the use of this
marker in the diagnosis of myocardial injury related to
surgical repair of congenital heart defect. These studies
demonstrate the application of the method in different
situations, since the diagnosis of events following the
performance of operative procedures to its use as a
prognostic marker [9-12].
Also, cTnI values have been presented as an important
method to assist in the management of other pediatric
diseases, such as in myocarditis [13], sepsis [14], and in
Kawasaki disease [15], diseases in which cardiac
dysfunction is a common event.
For an adequate use of biochemical markers in daily clinical
practice, it is necessary to define which reference values to
use [16]. Some studies have emerged with this purpose,
achieving results in pediatrics similar to those of adult
researches [17], however, others have presented increased
cTnI values in children under one year of age [18,19].
The definition in relation to the reference values for
cTnI in pediatrics and the importance of this diagnosis
method, by its characteristics and applicability, has
motivated this research.
METHODS
This research was undertaken after being approved by
the Research and Ethics Committee of the participant
institutions. This is a non-randomized, prospective
observational clinical trial to refine new diagnosis
approaches.
Between January 15 and February 13 2003, 99 children
under the age of one year were included in the study after
a written informed consent was signed by their legal
authorized representatives. cTnI values were then
measured.
The children enrolled in the study have met the following
inclusion criteria: age under 1 year, including full term
infants, no previous diagnosis of heart diseases, or any
clinical condition somehow related to cardiac dysfunction,
hemodynamic stability, determined through physical
examination without using drug therapy or mechanical
support.
The patients were divided into two groups according to
their age group. Group I consisted of newborns up to 28
days of life. Group II consisted of infants between 29 days
of life and one year. The newborns in group I have cTnI
values collected at the moment of nursery routine
examinations, and children in group II, at the moment of
preoperative ward examinations and for child care follow-
up; the exams were ordered by practitioners not involved
in the study.
The sample collection, storage, and assay followed the
manufactures guidelines and the pertinent literature.
Samples were collected using conventional peripheral
venipuncture techniques, preferably in the right cubital
region, using a disposable plastic syringe and needles with
no anticoagulant solution.
After sample collection, 2 mL of blood was poured into
a glass tube and set out for serum separation by means of
centrifugation at 3000 rpm for 10 minutes. Serum was stored
in a glass tube at +3ºC. Samples remained stored at an
average of 24 hours not surpassing a 72-hour period storage
until cTnI dosage.
A specific kit, Opus T Troponin I (cTn) test modules
(Dade Behring Inc. - Newalk, DE 19714, USA) and the device
Opus plus® analyzer (Behring Diagnostics Inc. - Westwood,
MA 02090, USA) were used to analyze the samples.
The assay is based on fluorogenic immunoassay
principles linked to a double antibody sandwich enzyme
(antibody-antigen-antibody), or linked to two sites with
mouse monoclonal antitroponin I antibodies.
Analysis was performed automatically by the Opus plus
analyzer.
Serum concentration is expressed in nanograms per
milliliter (ng/mL).
Method assay range varies from 0.1 to 50.0 ng/mL.
Assay analytic sensitivity is 0.1 ng/mL. All values below
are referred by the analyzer as < 0.1 ng/mL. The reference
value for normalization established by the laboratory is
lower than 0.5 ng/mL.
RESULTS
The study population consisted of 99 children
undergoing cTnI dosage divided into two groups: group I
consisted of 74 newborns, 35 males (3.18 ± 0.44 kg) and 39
females (3.14 ± 0.42 kg); group II consisting of 25 infants,
16 males (8.5 ± 2.4 kg) and 9 females (8.2 ± 1.0 kg).
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specific antibodies present in different methods and,
consequently, with its results [25].
The method used in our study, the Opus T Troponin I
(cTn) test modules (Dade Behring Inc. - Newalk, DE 19714,
USA) was chosen due to its commercial use and with which
an important ability in daily usage has been developed; in
addition, it was available at our institution.
The daily use of serum dosage of cTnI for AMI
diagnosis in adult patients through this diagnostic method
has yielded outcomes contrary to literature data regarding
sensibility, specificity, and temporal course, turning this
method into an important aid tool in the diagnosis and
follow-up of these patients [20].
As the method analytical sensitivity was set at 0.1 ng/
mL, our result did not allow the performance of statistical
processes. Likewise, with the analyzer Opus Plus assigning
values <0.1 ng/mL, our result was rather a qualitative
variable than a quantitative one, not showing variation.
Levin [26] defined Statistics as “…a set of techniques
to reduce quantitative data (i.e., a series of number) into a
more convenient and easily communicable number of
smaller descriptive terms”.
Taking into consideration the characterization of our
result and the definition proposed by Levin, we believe to
be justifiable not to apply a statistical outlining to our study,
however, this does not interfere in the assessment regarding
its applicability, once the distribution of all values below
0.1 ng/mL allows concluding that all patients presented
normal values, regardless its variation within this interval.
After assessing all data presented, it becomes difficult
to justify the findings of increased cTnI in normal children;
on the contrary, we believe these data cause our study
result to be expected, and they justify the incisive fashion
as this result turned to be, which has been repeated in
newly published studies [27,28].
Despite the variability in the results found among
different methods, the use of this myocardial injury
biochemical marker has been playing an important role in
patients’ diagnosis and follow-up. It is important that the
interpretation of the results in daily practice be carried out
relatively to local laboratory standards and comparatively
to other methods.
New studies are needed to investigate several aspects
related to the dosage of serum cTnI and its applicability.
CONCLUSION
We concluded that the reference value (0.1 ng/mL) for
serum cardiac troponin I dosage, when performed through
Opus T Troponin I (cTn) test modules (Dade Behring Inc.-
Group I infants were sampled in their first day of life,
except one who was sampled on the 13th day of life. Male
and female infants’ mean age (group II) at the moment of
sampling was 7.6 ± 2.8 months and 8.2 ± 1.9 months,
respectively.
The dosage of cTnI was found to be below the assay
analytic sensitivity level (0.1 ng/mL) in all children and it
was registered by the analyzer (Opus plus) as < 0.1 ng/mL.
DISCUSSION 
The results of our study are compatible with the
results of other studies which have observed normal
values of cTnI in pediatric patients without myocardial
injury [17]. The distribution of all values found within
the reference range for normality (<0.1 ng/mL) is not an
unexpected fact, once the literature data relates a high
specificity to the method [20] and the study population
did not present any clinical data suggesting the existence
of myocardial injury, which was established by the study
inclusion criteria.
Among the studies, we have found two publications
aiming at defining the reference values in a pediatric
population. The authors considered a new and exciting
datum to have as a result a large percentage of patients
in the first year of life presenting increased cTnI values
[18,19].
The abovementioned authors suggest that the
increased serum levels of cTnI is related with the apoptosis
of myocardial cells. However, it is difficult to establish this
relationship because apoptosis is a physiological
phenomenon playing an important role in the development
of several organs, being suppressed at the beginning of
extrauterine life, and despite of being named as cell death,
it occurs usually in isolated cells and it is not followed by
an inflammatory process. The cells undergo herniation of
cell membrane, volume reduction, condensation of nuclear
chromatin and, finally, they are phagocytosed by
macrophages and surrounding cells [21-23].
An important consideration to be made when different
study results are compared is the influence of the
methodology used. There is a great variability of results
between two methods [24].
This variability is related to a series of processes that
will change the cTnI presentation form after its release.
Only 10% of the released cTnI remains in its free form; the
other 90% build up complexes, especially with Troponin C;
moreover, cTnI can be submitted to other biochemical
processes, causing it to be oxidized or reduced. These
several changes interfere with the reaction of cTnI with the
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